Credit: Getty Images. Brexpiprazole is an atypical antipsychotic. The Food and Drug Administration (FDA) has approved Rexulti ® (brexpiprazole) for the treatment of agitation associated with dementia ...

Agitation and aggression are challenging behaviors that can happen in people with dementia, especially in Alzheimer’s disease. It can cause you or your relative to act out in different ways. You may ...

Dealing with mental health conditions like depression can be challenging. Some people struggle to find the right treatment or combination of treatments for their condition. In major depression ...

After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U.S., Lundbeck has raised its peak sales projection for the therapy in the key market. The Danish company now expects the ...

A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration. Rexulti (brexpiprazole) tablets can be used to treat adults with schizophrenia. The new ...

Rexulti (brexpiprazole) is a brand-name drug prescribed for certain mental health conditions. Rexulti comes as an oral tablet that’s typically taken once per day. The dosage can vary depending on what ...

The FDA issued a CRL for Rexulti's sNDA, citing insufficient evidence of effectiveness for PTSD treatment in combination with sertraline. The Psychopharmacologic Drugs Advisory Committee voted 1-10 ...

Otsuka and Lundbeck announced that the Food and Drug Administration (FDA) has approved the labeling update for Rexulti (brexpiprazole) to reflect clinical data for maintenance treatment of ...

Rexulti can interact with several other drugs, including certain antibiotics, seizure medications, and opioids. These interactions can either increase the risk of side effects or reduce Rexulti’s ...

On Friday, BofA Securities adjusted its stance on H Lundbeck A/S (HLUNB:DC) (OTC: HLUYY) stock, shifting from a Neutral to an Underperform rating. The investment firm maintained its price target for ...